» Articles » PMID: 17034116

Structure-based Design of Potent Small-molecule Inhibitors of Anti-apoptotic Bcl-2 Proteins

Abstract

A structure-based approach was employed to design a new class of small-molecule inhibitors of Bcl-2. The most potent compound 5 (TW-37) binds to Bcl-2 with a K(i) value of 290 nM and also to Bcl-xL and Mcl-1 with high affinities. Compound 5 potently inhibits cell growth in PC-3 prostate cancer cells with an IC(50) value of 200 nM and effectively induces apoptosis in a dose-dependent manner.

Citing Articles

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.

Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A Nat Commun. 2024; 15(1):2743.

PMID: 38548768 PMC: 10979003. DOI: 10.1038/s41467-024-46922-4.


Corosolic Acid Induced Apoptosis via Upregulation of Bax/Bcl-2 Ratio and Caspase-3 Activation in Cholangiocarcinoma Cells.

Jedram O, Maphanao P, Karnchanapandh K, Mahalapbutr P, Thanan R, Sakonsinsiri C ACS Omega. 2024; 9(1):1278-1286.

PMID: 38222611 PMC: 10785084. DOI: 10.1021/acsomega.3c07556.


AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.

Ailawadhi S, Parrondo R, Dutta N, Han B, Ciccio G, Cherukuri Y Cancers (Basel). 2023; 15(2).

PMID: 36672426 PMC: 9857228. DOI: 10.3390/cancers15020477.


Hypericin, a potential new BH3 mimetic.

Doroshenko A, Tomkova S, Kozar T, Stroffekova K Front Pharmacol. 2022; 13:991554.

PMID: 36267274 PMC: 9577225. DOI: 10.3389/fphar.2022.991554.


Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells.

Osterlund E, Hirmiz N, Pemberton J, Nougarede A, Liu Q, Leber B Sci Adv. 2022; 8(16):eabm7375.

PMID: 35442739 PMC: 9020777. DOI: 10.1126/sciadv.abm7375.